TRDA (Entrada Therapeutics) Gross Profit : $210.8 Mil (TTM As of Dec. 2024)

Entrada Therapeutics Gross Profit Chart

Entrada Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross Profit	Get a 7-Day Free Trial															41.85	59.12	94.69	19.57	37.40

Competitive Comparison of Entrada Therapeutics's Gross Profit

For the Biotechnology subindustry, Entrada Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Gross Profit falls into.

Entrada Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Entrada Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Entrada Therapeutics's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $210.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Entrada Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Entrada Therapeutics  (NAS:TRDA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Entrada Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

Entrada Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics Business Description